These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 3285914)

  • 41. Posterior reversible encephalopathy syndrome (PRES) during induction chemotherapy for acute myeloblastic leukemia (AML).
    Battipaglia G; Avilia S; Morelli E; Caranci F; Perna F; Camera A
    Ann Hematol; 2012 Aug; 91(8):1327-8. PubMed ID: 22237936
    [No Abstract]   [Full Text] [Related]  

  • 42. Long-term follow-up of a randomized post-induction therapy trial in acute myelogenous leukemia (a Southeastern Cancer Study Group trial).
    Volger WR; Weiner RS; Moore JO; Omura GA; Bartolucci AA; Stagg M
    Leukemia; 1995 Sep; 9(9):1456-60. PubMed ID: 7544851
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Increased mortality with FLA compared with ADE chemotherapy in high-risk AML.
    Lane SW; Marlton P; Mollee PN
    Blood; 2006 Dec; 108(12):3950-1; author reply 3951. PubMed ID: 17114571
    [No Abstract]   [Full Text] [Related]  

  • 44. Intensive consolidation chemotherapy versus standard consolidation maintenance in acute myelogenous leukemia (AML) in first remission. An EORTC/GIMEMA phase III trial (AML8 B). The EORTC Leukemia Cooperative Group and the GIMEMA Group.
    Zittoun R; Liso V; Mandelli F; Rotoli B; de Witte T; Gattringer C; Resegotti L; Caronia F; Leoni P; Petti MC
    Leukemia; 1992; 6 Suppl 2():76-7. PubMed ID: 1578949
    [No Abstract]   [Full Text] [Related]  

  • 45. Acute myelogenous leukaemia: maintenance chemotherapy after early consolidation treatment does not prolong survival.
    Sauter C; Berchtold W; Fopp M; Gratwohl A; Imbach P; Maurice P; Tschopp L; von Fliedner V; Cavalli F
    Lancet; 1984 Feb; 1(8373):379-82. PubMed ID: 6141436
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Questions regarding frontline therapy of acute myeloid leukemia.
    Kantarjian H; O'Brien S
    Cancer; 2010 Nov; 116(21):4896-901. PubMed ID: 20623787
    [No Abstract]   [Full Text] [Related]  

  • 47. Influence of daunorubicin and cytarabine sequencing on the outcome of therapy in acute myelogenous leukemia: a randomized trial.
    Archimbaud E; Fiere D; Treille-Ritouet D; Adeleine P; Guyotat D; Sebban C; Vuvan H; Viala JJ
    Cancer Treat Rep; 1987 Jun; 71(6):571-4. PubMed ID: 3555788
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Treatment of acute non-lymphoblastic leukemia in adults. Preliminary report from the national protocol on antineoplastic drugs].
    Gutiérrez J; García H; Osorio G; Vacarezza R; Cao C
    Rev Med Chil; 1990 Apr; 118(4):473-80. PubMed ID: 2133162
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Aclarubicin plus cytosine arabinoside versus daunorubicin plus cytosine arabinoside in previously untreated patients with acute myeloid leukemia: a Danish national phase III trial. The Danish Society of Hematology Study Group on AML, Denmark.
    Hansen OP; Pedersen-Bjergaard J; Ellegaard J; Brincker H; Boesen AM; Christensen BE; Drivsholm A; Hippe E; Jans H; Jensen KB
    Leukemia; 1991 Jun; 5(6):510-6. PubMed ID: 2056774
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Long-term treatment and prognostic factors in adult acute myeloblastic leukemia. Experience of the INNSZ group Puebla-Monterrey-Mexico)].
    Lobato-Mendizabal E; Ruiz-Argüelles GJ; Gómez-Almaguer D; Ganci-Cerrud G; Lozano de la Vega A; Labardini-Méndez J
    Rev Invest Clin; 1991; 43(3):215-22. PubMed ID: 1818368
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Second cycle remission achievement with 7+3 and survival in adults with newly diagnosed acute myeloid leukemia: analysis of recent SWOG trials.
    Othus M; Estey EH; Garcia-Manero G; Wood BL; Stirewalt DL; Godwin JE; Weick JK; Anderson JE; Appelbaum FR; Erba HP; Walter RB
    Leukemia; 2019 Feb; 33(2):554-558. PubMed ID: 30315233
    [No Abstract]   [Full Text] [Related]  

  • 52. [Intensive post-remission therapy in acute myeloid leukemia. Results of a prospective comparative study by the South Germany Hemoblastosis Group].
    Hübner G; Link H; Schönrock-Nabulsi P; Wandt H; Gramatzki M; Löffler B; Fackler-Schwalbe I; Queisser W; Brack N; Geer T; Raab M; Ohl S; Schneider B; Schneider C; Freund M; Poliwoda H; Ehninger G
    Med Klin (Munich); 1996 Apr; 91 Suppl 3():26-32. PubMed ID: 8692115
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Liposomal daunorubicin, fludarabine, and cytarabine (FLAD) as bridge therapy to stem cell transplant in relapsed and refractory acute leukemia.
    De Astis E; Clavio M; Raiola AM; Ghiso A; Guolo F; Minetto P; Galaverna F; Miglino M; Di Grazia C; Ballerini F; Marani C; Pastori G; Mitscheunig L; Cruciani F; Lovera D; Varaldo R; Ghiggi C; Lemoli RM; Bacigalupo A; Gobbi M
    Ann Hematol; 2014 Dec; 93(12):2011-8. PubMed ID: 24989345
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Intensive consolidation chemotherapy for acute lymphoblastic leukaemia (UKALL X pilot study).
    Pinkerton CR; Bowman A; Holtzel H; Chessells JM
    Arch Dis Child; 1987 Jan; 62(1):12-8. PubMed ID: 3468886
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Long-term outcome of adults with acute myelogenous leukaemia: results of a prospective, randomized study of chemotherapy with a minimal follow-up of 7 years.
    Bandini G; Zuffa E; Rosti G; Battista R; D'Emilio E; Leoni F; Ciolli S; Barbui T; Bassan R; Todeschini G
    Br J Haematol; 1991 Apr; 77(4):486-90. PubMed ID: 2025573
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Age adapted induction and intensified consolidation therapy in acute myelogenous leukemia.
    Kurrle E; Ehninger G; Freund M; Heil G; Hoelzer D; Link H; Mitrou PS
    Onkologie; 1986 Jun; 9(3):141-3. PubMed ID: 3528959
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Effect of granulocyte colony-stimulating factor on outcomes in patients with non-M3 acute myelogenous leukemia treated with anthracycline-based induction (7+3 regimen) chemotherapies.
    Kang KW; Kim DS; Lee SR; Sung HJ; Kim SJ; Choi CW; Kim BS; Park Y
    Leuk Res; 2017 Jun; 57():1-8. PubMed ID: 28231491
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Intensified induction and consolidation with or without maintenance chemotherapy for acute myeloid leukemia (AML): two multicenter studies of the German AML Cooperative Group.
    Büchner T; Urbanitz D; Hiddemann W; Rühl H; Ludwig WD; Fischer J; Aul HC; Vaupel HA; Kuse R; Zeile G
    J Clin Oncol; 1985 Dec; 3(12):1583-9. PubMed ID: 3906048
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Induction and intensive combined therapy of acute myeloid leukemia in adults].
    Kurrle E; Ehninger G; Freund M; Heil G; Hoelzer D; Link H; Mitrou PS; Ohl S; Queisser W; Schlimok G
    Onkologie; 1988 Feb; 11(1):5-9. PubMed ID: 3283626
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Post-remission cytopenias following intense induction chemotherapy for acute myeloid leukemia.
    Damon LE; Rugo HS; Ries CA; Linker CA
    Leukemia; 1994 Apr; 8(4):535-41. PubMed ID: 8152248
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.